

AMENDMENT

Page 2

Atty Docket No. 933.001USR

Reissue Application of Mark Lyte

COMPOUNDS FOR MODULATING GROWTH OF INFECTIOUS AGENTS

8. *The method of claim 4 wherein said catecholamine is selected from the group consisting of norepinephrine, epinephrine, and dopamine.*
9. *The method of claim 5 wherein said catecholamine is selected from the group consisting of norepinephrine, dopamine and epinephrine.*
10. *A method of enhancing the growth of Gram-negative bacteria in a host medium said host medium being selected from the group consisting of in vitro and cell cultures, said method comprising the introduction of an effective amount of a catecholamine to the host medium to enhance the growth of said Gram-negative bacteria.*
11. *The method of claim 10 wherein said catecholamine is selected from the group consisting of norepinephrine, epinephrine and dopamine.*
12. *A method for harvesting the by-products of enhanced growth of bacteria or viruses comprising introducing an effective amount of a catecholamine to an in vitro or cell culture host medium of bacteria or virus to act directly on enhancing the growth of said bacteria or viruses, and collecting by-products generated by said bacteria or viruses.*
13. *The method of claim 12 wherein said introduction of said catecholamine acts directly on enhancing the growth of said bacteria or virus.*
14. *The method of claim 12 wherein a Gram-negative bacteria undergoes said enhanced growth.*
15. *The method of claim 13 wherein a Gram-negative bacteria undergoes said enhanced growth.*
16. *The method of claim 14 wherein said Gram-negative bacteria is selected from the group consisting of E. coli and Y. enterocolitica.*

17. *The method of claim 13 wherein an inhibitor is determined which intercedes at any point in a catecholamine biosynthetic pathway, and Gram-negative bacteria are subsequently treated by said inhibitor.*

18. *The method of claim 14 wherein an inhibitor is determined which intercedes at any point in a catecholamine biosynthetic pathway, and Gram-negative bacteria are subsequently treated by said inhibitor.*

19. *The method of claim 13 wherein said catecholamine is selected from the group consisting of norepinephrine, epinephrine, and dopamine.*

20. *The method of claim 14 wherein said catecholamine is selected from the group consisting of norepinephrine, epinephrine, and dopamine.*

21. *A method for harvesting the by-products of enhanced growth of bacteria or viruses comprising introducing an effective amount of a catecholamine to an in vitro or cell culture host medium of bacteria or virus to act directly on enhancing the growth of said bacteria or viruses, and collecting by-products other than glucose generated by said bacteria or viruses.*

22. *The method of claim 21 wherein said enhanced growth is effected on bacteria and said bacteria comprises Gram-negative bacteria.*

REMARKS CONCERNING THE PROSECUTION HISTORY OF THE APPLICATION WHICH ULTIMATELY ISSUED AS U.S. PATENT NO. 5,629,349

The original U.S. Patent Application (07/847196, filed March 6, 1992), the File Wrapper Continuation of which ultimately issued as U.S. Patent No. 5,629,349 (hereinafter the "LYTE Patent"), had a claim therein which was as follows:

"1. A method for affecting the growth of vectors and cell cultures and living organisms, said vectors and cell cultures and living organisms being characterized by the presence of at least